首页 / 院系成果 / 成果详情页

The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia 期刊论文

编号：

b9359e59-fb76-4c9a-aaea-7c963e63b7ff
作者：

Cui, Lifeng(崔丽峰)#^[1]Shu, Chang(舒畅)*^[2]Liu, Zitao^[3];Tong, Weihua(佟伟华)^[4]Cui, Miao^[5];Wei, Chengguo^[6];Tang, Jian Jenny^[7];Liu, Xiufen(刘秀芬)^[8]Hu, Jinghai^[9];Jiang, Jing(姜晶)^[10]He, Jin(何津)^[2]Zhang, David Y.^[5];Ye, Fei*^[5]Li, Yulin(李玉林)*^[1]
语种：

英文
期刊：

PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH ISSN：2210-7789 2018 年 13 卷 (127 - 132) ; JUL
收录：
关键词：

sEGFR sFlt-1 sEndoglin PLGF Term preeclampsia Preterm preeclampsia
摘要：

The objective of this study was to investigate soluble epidermal growth factor receptor (sEGFR), soluble vascular endothelial growth factor receptor 1 (sFlt-1), soluble endoglin (sEndoglin) and placenta growth factor (PLGF) concentrations in normotensive, preterm and term preeclamptic pregnancies' serum and thus to specify the clinical utility of these biochemical markers in monitoring severity and intrauterine growth retardation of preterm preeclampsia. 172 pregnant women were divided into the following groups: preterm preeclampsia, preterm control, term preeclampsia and term control. Preterm preeclampsia patients were stratified with severe feature (n = 50) and without severe feature (n = 22). sEGFR, sEndoglin and PLGF were assessed using Luminex multiplex immunoassay, whilesFlt-1 was assessed using ELISA. sEGFR was significantly lower in preterm preeclampsia than matched control (p < 0.001) and mildly lower in term preeclampsia than matched control (p < 0.01). On contrary, sFlt-1 was significantly higher in preterm preeclampsia than matched control (p < 0.001) and mildly higher in term preeclampsia than matched control (p < 0.01). sFlt-1, sFlt-1/sEGFR and sFlt-1/PLGF were positively correlated with the severity of preterm preeclampsia (P < 0.001, R value >= 0.6), especially sFlt-1/sEGFR had the highest R value (R value = 0.711) among them. Furthermore, sEndoglin and the ratio of sEndoglin/sEGFR were associated with neonatal birth weight small for gestational age (SGA, n = 25) in preterm preeclampsia group. Conclusions: The ratio of sFlt-1/sEGFR could be used as a novel candidate biochemical marker in monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR may be involved in the pathogenesis of SGA in preterm preelampsia.
推荐引用方式
GB/T 7714：

Cui Lifeng,Shu Chang,Liu Zitao, et al. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia [J].PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH,2018,13:127-132.
APA：

Cui Lifeng,Shu Chang,Liu Zitao,Tong Weihua,&Li Yulin.(2018).The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia .PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH,13:127-132.
MLA：

Cui Lifeng, et al. "The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia" .PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH 13(2018):127-132.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：60  下载次数：0

分享到：

浏览次数：60

下载次数：0

打印次数：0